Ferozsons Laboratories, BioGaia to sell probiotic drops and tablets in Pakistan

NewsGuard 100/100 Score

Today BioGaia (STO:BIOG) has signed an agreement with Ferozsons Laboratories Limited, for the exclusive rights to sell BioGaia's probiotic drops and tablets in Pakistan. The products will be sold under the BioGaia brand and launch is planned to 2013.

Ferozsons Laboratories Limited (http://www.ferozsons-labs.com/) is one of Pakistan's leading pharmaceutical companies. Several of the company's brands are market leaders in the fields of gastroenterology, cardiology and oncology. Ferozsons Laboratories Limited is focused on medical marketing and has a large medical field force. The company has been listed on Pakistan's three Stock Exchanges since 1960.

Both the BioGaia ProTectis baby drops and the BioGaia ProTectis tablets contain BioGaia's patented and well researched probiotic strain Lactobacillus reuteri Protectis. Today the drops are available in 52 countries and the tablets in 46 countries.

"We are pleased with the agreement with Ferozsons Laboratories Limited. As Pakistan has a population of 187 million people - the world's sixth most populous - and in addition a large proportion is children, the potential for our probiotic products should be good", says Peter Rothschild, Chief Executive Officer, BioGaia.

Source:

BioGaia    

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revolutionizing critical care: the potential of gut microbiota therapeutics